The Gantenerumab Trial
This study looks at an exciting opportunity to get involved in testing new medication for people with Alzheimer’s Disease.
Aims of the Study
Alzheimer’s disease is a major global public health problem, and there are nearly 30 million people with the disease worldwide.
Alzheimer’s disease is an irreversible, progressive neurodegenerative disease which causes a gradual decline in memory and thinking skills.
Currently, there is no cure for Alzheimer’s disease and available treatments cannot stop the disease from progressing as they do not affect the underlying causes of the disease.
Instead they can help to alleviate symptoms and improve quality of life.
The aim of the study is to advance the understanding of Alzheimer’s disease to inform the development of future treatment options.
The study will test whether an investigational medication called Gantenerumab can help maintain memory and day-to-day living in people with mild Alzheimer’s disease.
To take part in the research study, participants must:
1. Be between the ages of 50 and 90.
2. Have a family member or friend, with whom they are in regular contact, who can accompany them to study visits.
3. Be interested in taking part in a study lasting approximately three years.
4. Have been told by their doctor that they have or probably have mild Alzheimer’s disease.
About 1,000 patients with mild Alzheimer’s disease will participate in the study in more than 200 centres across the world.
Study participation will last for approximately three years and those interested in taking part will be asked to attend a screening visit to make sure they are eligible to participate.
Whilst taking the medication, volunteers will be asked to undergo assessments of their memory and thinking, provide samples of blood, urine and spinal fluid, and take part in scans of the brain.
Volunteers can see if they are eligible for this study – and for the many others available – by signing up with ‘Join dementia research’.
Let us know!
We always want to hear from people taking part in ‘Join dementia research’ studies!
Do you find it rewarding to take part in research? What would you say to others considering joining dementia research?